The Technical Analyst
Akoya Biosciences, Inc. [AKYA]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Instruments & Supplies
Akoya Biosciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.52% $3.80
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 187.64 mill |
| EPS: | -1.430 |
| P/E: | -2.66 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 49.38 mill |
| Avg Daily Volume: | 0.183 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.66 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.08x |
| Company: PE -2.66 | industry: PE 33.06 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.48 - 4.12 ( +/- 8.42%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Ek John Frederick | Sell | 14 272 | Common Stock |
| 2024-03-23 | Pla Frederic | Sell | 2 006 | Common Stock |
| 2024-03-23 | Ramachandran Niro Ph.d | Sell | 2 006 | Common Stock |
| 2024-03-23 | Mckelligon Brian | Sell | 7 135 | Common Stock |
| 2024-03-20 | Mckelligon Brian | Sell | 7 500 | Employee Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 67.47 |
| Last 99 transactions |
| Buy: 5 199 597 | Sell: 937 556 |
Forecast:
16:00 - $3.80
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.80
Forecast 2: 16:00 - $3.80
Forecast 3: 16:00 - $3.80
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.80 (-0.52% ) |
| Volume | 0.0922 mill |
| Avg. Vol. | 0.183 mill |
| % of Avg. Vol | 50.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AKYA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 6 - 13:14 | buy | $5.71 | N/A | Active |
|---|
AKYA
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Latest Press Releases
2024-04-22 16:05:00 - Press Release
Akoya To Report First Quarter 2024 Financial Results On May 13th, 2024
Marlborough, mass., april 22, 2024 (globe newswire) -- akoya biosciences, inc. (nasdaq: akya) (“akoya”), the spatial biology company®, today announced that it will release financial results for the first quarter of 2024 after the market close on may 13th, 2024. company management will host a conference call to discuss financial results at 5:00 p.m. et.
2024-04-05 08:00:00 - Press Release
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions At Aacr Annual Meeting With Case Studies Demonstrating Unprecedented Speed And Scale
Marlborough, mass., april 05, 2024 (globe newswire) -- akoya biosciences, inc., (nasdaq: akya), the spatial biology company®, today announced it will highlight case studies featuring its spatial biology 2.0 solutions that enable unprecedented speed and scale for spatial biology studies at the american association for cancer research (aacr) 2024 annual meeting in san diego, april 5 to 10. in addition, the company will showcase new applications of its phenocode™ signature panels and preliminary data from the thermo fisher viewrna assays on akoya's platforms.
2024-03-19 07:00:00 - Press Release
Akoya Biosciences Names Bostongene As A Qualified Cro Service Provider
Waltham, mass.--(business wire)--bostongene, a leading provider of ai-driven molecular and immune profiling solutions, announced today that it has been named as a qualified contract research organization (cro) of akoya biosciences (nasdaq: akya; “akoya”). by combining akoya's single-cell imaging solutions with bostongene's unparalleled expertise in spatial proteomics sample processing and analysis, researchers will gain unprecedented access to the intricate landscape of cellular biology, paving.
2024-03-04 16:05:00 - Press Release
Akoya Reports Record Revenue In The Fourth Quarter Of 2023 And Provides Full Year 2024 Financial Outlook
Q4 2023 revenue $26.5 million and fy 2023 revenue $96.6 million guiding fy 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by ye 2024
2024-02-08 16:05:00 - Press Release
Akoya To Report Fourth Quarter And Full Year 2023 Financial Results On March 4th, 2024 And Participate At An Upcoming Investor Conference
Marlborough, mass., feb. 08, 2024 (globe newswire) -- akoya biosciences, inc. (nasdaq: akya) (“akoya”), the spatial biology company®, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on march 4th, 2024. company management will host a conference call to discuss financial results at 5:00 p.m. et.
Latest News
2024-04-22 16:05:00 - GlobeNewsWire
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2024 after the market close on May 13th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
2024-03-04 20:17:08 - Seeking Alpha
Akoya Biosciences, Inc. (AKYA) Q4 2023 Earnings Call Transcript
Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q4 2023 Earnings Conference Call March 4, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants Subbu Nambi - Guggenheim Kyle Mikson - Canaccord Tejas Savant - Morgan Stanley John Sourbeer - UBS Mark Massaro - BTIG Rachel Vatnsdal - JP Morgan Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Fourth Quarter 2023 Earnings Conference Call.
2024-03-04 18:16:05 - Zacks Investment Research
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.50 per share a year ago.
2024-02-08 16:05:00 - GlobeNewsWire
Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference
MARLBOROUGH, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on March 4th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
2024-02-07 05:16:23 - Zacks Investment Research
Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?
Akoya (AKYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2024-01-08 11:17:44 - Zacks Investment Research
5 Small-Cap Stocks to Play the January Effect
Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.
2024-01-08 11:17:43 - Zacks Investment Research
Best Momentum Stocks to Buy for January 8th
AKYA, DRTS and TRUP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024.
2024-01-08 07:31:19 - Zacks Investment Research
New Strong Buy Stocks for January 8th
TIMB, AKYA, DRTS, TRUP and QSG have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024.
2024-01-05 09:46:18 - Zacks Investment Research
How Akoya Biosciences (AKYA) Stock Stands Out in a Strong Industry
Akoya Biosciences (AKYA) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
2023-12-27 11:17:44 - Zacks Investment Research
How Much Upside is Left in Akoya (AKYA)? Wall Street Analysts Think 86%
The average of price targets set by Wall Street analysts indicates a potential upside of 86% in Akoya (AKYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.